Binding Site Release: Optilite, The Latest Innovation In Special Protein Testing, Launches In North America

Binding Site leverages over 30 years of expertise in special protein diagnostics with new system

SAN DIEGO--(BUSINESS WIRE)--Binding Site, the world leader in special protein diagnostics, announces the North American launch of Optilite, the company’s revolutionary, fully-automated special protein analyzer. Optilite is the first dedicated benchtop special protein analyzer on the market since the company launched its own SPAPLUS® instrument in 2006, and is specifically designed for laboratory workflow optimization. Data from laboratories running Optilite show 40% faster processing of complex protein assays compared to other special protein analyzers on the market today.

“The result is Optilite, the latest innovation in special protein testing, which offers laboratories reliability, accurate results, speed and efficiency.”

“We wanted to bring simplicity to complex analytical processes,” said Charles de Rohan, CEO of Binding Site. “The result is Optilite, the latest innovation in special protein testing, which offers laboratories reliability, accurate results, speed and efficiency.”

Optilite’s continuous loading of samples, reagents, and consumables plus automatic re-dilution to end result enable labs to maximize test throughput while minimizing hands-on time. A comprehensive menu of special protein assays, including Binding Site’s Freelite® test, is currently available with additional assays under development. The Optilite system and current menu are FDA cleared and Health Canada registered.

With a compact benchtop design, Optilite is quick to install, easy to maintain, and is equipped with full LIS connectivity and automatic barcode recognition for full traceability.

Unique to Optilite is a robust antigen excess protection system with three detection methods, thereby ensuring accurate and reliable results.

“Optilite combines Binding Site’s latest instrument technology with our assays, which are optimized to run specifically on this platform,” said Doug Kurth, President of Binding Site Inc. “The Optilite system is the complete protein solution for today’s market.”

About Binding Site

Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. The company focuses on research, development, manufacture and distribution of innovative immunodiagnostic systems and assays for the global laboratory market. By utilizing its specialized expertise in antibody specificity technology, Binding Site has developed a broad menu of special protein assays, including the Freelite test, the only FDA cleared and guideline-recommended serum free light chain assay on the market. Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders.

For more information about Binding Site, please visit www.thebindingsite.com